Sean Callahan, MD
Pulmonary Disease · Greenville, SCNPI 1043505670
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $247,532 of the $321,003 with a category attached, or 77.1%. Noah Medical Corporation accounts for 81.4% of it on its own, with 36 other manufacturers making up the rest. Among pulmonary disease clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 389 payments — averaging $825.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Noah Medical Corporation$261K
- Johnson & Johnson$33K
- Ethicon Endo-surgery Inc.$7K
- Pinnacle Biologics, Inc$4K
- Intuitive Surgical$3K
- Pulmonx Corporation$3K
- plus $10K from 31 others
Across 12 payments — averaging $15,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson$140K
- Boehringer Ingelheim$27K
- Boehringer Ingelheim Pharma GmbH & Co.kg$13K
What the payments were for
- Consulting fees$247,53277%
- Speaking & faculty fees$19,8756%
- Travel & lodging$34,33311%
- Food & beverage$19,2516%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Noah Medical Corporation | 120 | $261,392 |
| Johnson & Johnson(2 entities) | 49 | $32,974 |
| Ethicon Endo-surgery Inc. | 3 | $7,238 |
| Pinnacle Biologics, Inc | 9 | $3,935 |
| Intuitive Surgical | 13 | $2,636 |
| Pulmonx Corporation | 16 | $2,581 |
| Biomerieux Inc | 1 | $2,112 |
| Boehringer Ingelheim | 20 | $1,248 |
| Medical Device Business Services, Inc. | 7 | $1,170 |
| Boston Scientific | 6 | $959 |
| Galvanize Therapeutics, Inc | 6 | $893 |
| Medtronic | 6 | $622 |
| GSK | 28 | $552 |
| Inari Medical, Inc. | 2 | $377 |
| Insmed, Inc. | 16 | $294 |
| Electromed, Inc. | 36 | $290 |
| Edwards Lifesciences | 2 | $247 |
| AstraZeneca | 9 | $223 |
| Abiomed | 2 | $201 |
| Merck | 10 | $188 |
| Ambu Inc. | 3 | $179 |
| Genentech USA, Inc. | 1 | $144 |
| Regeneron Healthcare Solutions, Inc. | 2 | $139 |
| Sunovion Pharmaceuticals Inc. | 6 | $85 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Philips North America LLC | 3 | $49 |
| Olympus Corporation Of The Americas | 1 | $44 |
| Baxter Healthcare | 1 | $26 |
| Astellas Pharma US Inc | 1 | $23 |
| United Therapeutics Corporation | 1 | $23 |
| Sanofi | 1 | $18 |
| La Jolla Pharmaceutical Company | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $15 |
| Grifols USA, LLC | 1 | $14 |
| Resmed Corp | 1 | $12 |
| Circassia Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GALAXY$244,853
- Monarch Platform$4,458
- Photofrin$3,804
- Da Vinci Surgical System$2,327
- Pulmonx Endobronchial Valve EBV$1,348
- MONARCH$1,151
- ALIYA SYSTEM$893
- CHARTIS CATHETER$789
- ZEPHYR DELIVERY CATHETER$789
- ZEPHYR ENDOBRONCHIAL VALVE$789
- PULMONX CHARTIS TABLET CONSOLE$789
- FLOWTRIEVER CATHETER, S$556
- ILLUMISITE$536
- CT THROMBECTOMY SYSTEM KIT$199
- Impella$146
- XOLAIR$144
- Arikayce$127
- ANORO$122
- DUPIXENT$114
- OFEV$104
How this compares
$321,003 in reported general payments places this provider in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 147 | $117,485 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $27,074 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $13,848 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $12,237 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $9,928 |
| Spiriva RespimatTiotropium Bromide | 17 | $9,513 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $6,839 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $6,093 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $4,301 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 124 | $4,212 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 27 | $3,832 |
| Wixela InhubFluticasone Propion/Salmeterol | 13 | $1,403 |
| Ventolin HfaAlbuterol Sulfate | 13 | $702 |
| Montelukast Sodium | 51 | $424 |
| Azelastine Hcl | 13 | $205 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $552 | $154,487219 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,248 | $30,20057 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $223 | $18,33025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Greenville
- Daniel Lo VerdeGreenville$14K
- Michael KasterGreenville$13K
- Ezzat El BayoumiGreenville$8K
- Azim SurkaGreenville$8K
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.